Triple protection of SGLT2i – ACT2DAY for patients' future

This promotional meeting is for UK-registered healthcare professionals only and is supported and funded by A. Menarini Farmaceutica Internazionale SRL including honoraria in accordance with the ABPI code of practice.

Join us for a free webinar exploring the triple benefits of SGLT2 inhibitors in type 2 diabetes – glycaemic, cardiovascular, and renal protection – and how early intervention can change the course of care.

Date: Wednesday 14th May 2025

Time: 19:00 – 20:30

Co-chairs: Professor Stephen Bain and Dr Amrit Lamba

What you’ll learn:

·      Why early glycaemic control with SGLT2i matters

·      The cardiovascular benefits of canagliflozin

·      Who benefits most from early kidney protection

·      How to deliver holistic cardio-renal-metabolic care

·      Practical insights on overcoming barriers to early therapy

Don’t miss this opportunity to enhance your clinical approach and futureproof patient care in type 2 diabetes.

Book your place here.

This promotional meeting is for UK-registered healthcare professionals only and is supported and funded by A. Menarini Farmaceutica Internazionale SRL including hospitality & honoraria in accordance with the ABPI code of practice.

Click here for Invokana® (canagliflozin) Prescribing Information

Reference: Invokana (canagliflozin) SmPC. 

Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise, either in addition to other T2D medicinal products or as monotherapy when metformin is considered inappropriate. [Refer to SmPC for complete indications]

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard. Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL on 0800 085 8678 or by email: menarini@medinformation.co.uk

PP-IN-UK-2749 | April 2025